GA-THE-COCA-COLA-COMPANY
10.4.2024 12:01:33 CEST | Business Wire | Press release
The Coca-Cola Company, the longest-running partner of the Olympic Games, today unveiled “Celebrate Everyday Greatness,” its theme for Paris 2024 and its global roster of athletes for Team Coca-Cola.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240410031180/en/
Coca-Cola Paris 2024 Global Roster (Photo: Business Wire)
Celebrate Everyday Greatness is designed to champion life’s everyday moments – both big and small – that create magic that builds into something great. The Coca-Cola Company is focused on helping to make Paris 2024 the most spectacular Olympic and Paralympic Games ever, with activations across a portfolio of brands that engage fans and athletes while delivering a more sustainable experience.
“The Olympic and Paralympic Games are a prime opportunity for The Coca-Cola Company and our extensive portfolio of products to connect with fans,” said Brad Ross, VP Global Sports & Entertainment Marketing and Partnerships. “We will use this global stage to showcase how greatness in everyday moments can create real magic.”
In its role as a Worldwide Partner of the Olympic and Paralympic Games and Presenting Partner of the Paris 2024 Olympic Torch Relay, The Coca-Cola Company will refresh athletes, officials and spectators with its wide product portfolio of beverages.
Team Coca-Cola Paris 2024 Global Roster
The Olympic and Paralympic Games show that magic happens when the world comes together. Team Coca-Cola includes some of the world’s greatest athletes across different sports, countries and abilities. They represent the latest generation of outstanding stories to continue the company’s nearly century-long partnership with the Olympic Games.
“The pressure to perform can be overwhelming, especially when so many people rely on you to be your best, day-in and day-out,” said global soccer star and Team Coca-Cola athlete Debinha. “This is my third time competing in the Olympic Games. This year, I've made it a point to let those around me know how much they motivate me to be great, on and off the field, every day.”
The Coca-Cola Company Sustainability at Paris 2024
The Coca-Cola Company’s ambition is to have an Olympic and Paralympic Games without waste. The company will be providing packaging options to help minimize waste and reduce carbon emissions.
Coca-Cola will also work to collect and recycle bottles to give them new life or so that they can be refilled. This includes drink and water fountains with refill options, returnable glass bottles and bottles made with recycled materials. Coca-Cola products will be transported more sustainably during last-mile delivery. Low-carbon vehicles powered by electric, biogas or hydrogen will be used to deliver products to competition site venues and the Athletes’ Village.
Additional activations, both online and on the ground, throughout Paris 2024 will unite consumers in celebrating the magic of the Olympic and Paralympic Games. For more information on The Coca-Cola Company’s Paris 2024 activities, visit coca-colacompany.com.
Team Coca-Cola Roster:
Alberto Abarza (Chile, Swimming), Ellie Carpenter (Australia, Football), Linda Motlhalo (South Africa, Football), Alex Greenwood (England, Football), Emma Twigg (New Zealand, Rowing), Katie Bowen (New Zealand, Football), Lydia Williams (Australia, Football), Alex Morgan (U.S., Football), Florian Jouanny (France, Para Cycling), Mathilde Gros (France, Track Cycling), Alyssa Naehar (U.S., Football), Harrie Lavreysen (Netherlands, Cycling), Ramesh Budihal (India, Surfing), Athing Mu (U.S., Track & Field), Huynh Nhu (Vietnam, Football), Sarina Bolden (Philippines, Football), CJ Bott (New Zealand, Football), Ji So-Yun (South Korea, Football), Sean McColl (Canada, Sport Climbing), Daniel Smrokowski (U.S., Basketball), Kadeena Cox (U.K., Para Cycling & Para Athletics), Tyler Wright (Australia, Surfing), Debinha (Brazil, Football), Kadeisha Buchanan (Canada, Football), Wu Hai Yan (China, Football), Dimitrij Ovtcharov (Germany, Table Tennis)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410031180/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom